Continued metformin beneficial for diabetes with cirrhosis

Continued metformin beneficial for diabetes with cirrhosis

(HealthDay)—Continuation of metformin therapy may improve survival in diabetes patients who are diagnosed with cirrhosis, according to research published in the December issue of Hepatology.

Xiaodan Zhang, of the Mayo Clinic College of Medicine in Rochester, Minn., and colleagues conducted a retrospective study of 250 patients with diabetes who were receiving metformin at the time of diagnosis with cirrhosis. The effect of continued therapy with metformin on survival was investigated.

The researchers found that 172 patients continued metformin therapy and 78 patients discontinued the medication. Median survival was longer in patients who continued metformin than in those who did not (11.8 versus 5.6 years overall; P < 0.0001). Similar patterns were observed for patients with Child-Pugh A scores or Child-Pugh B/C scores. Following multivariable adjustment, continued therapy with metformin remained an independent predictor of improved survival (hazard ratio, 0.43; P = 0.005). During follow-up, none of the patients experienced metformin-related lactic acidosis.

"Continuation of after cirrhosis diagnosis reduced the risk of death by 57 percent," the authors write. "Metformin should therefore be continued in diabetic with if there is no specific contraindication."


Explore further

Study reverses current thought on treatment of cirrhosis

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Hepatology

Copyright © 2014 HealthDay. All rights reserved.

Citation: Continued metformin beneficial for diabetes with cirrhosis (2014, December 9) retrieved 6 December 2019 from https://medicalxpress.com/news/2014-12-metformin-beneficial-diabetes-cirrhosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments